Overview
Clinical Meaning
Advanced RA management requires the NP to apply treat to target (T2T) principles with DAS28 scoring for disease activity assessment.
Advanced RA management requires the NP to apply treat-to-target (T2T) principles with DAS28 scoring for disease activity assessment. The DAS28 incorporates tender joint count (28 joints), swollen joint count, ESR or CRP, and patient global assessment. Target: DAS28 <2.6 (remission) or <3.2 (low disease activity). Treatment algorithm: start methotrexate 15 mg/week escalating to 25 mg/week within 8 weeks; if target not reached by 3-6 months, add or switch to biologic DMARD. Biologic selection is guided by mechanism and comorbidities: TNF inhibitors (etanercept, adalimumab, infliximab) are first-line biologics — avoid in CHF (NYHA III-IV), active hepatitis B, or demyelinating disease. IL-6 inhibitors (tocilizumab) — monitor lipids and avoid with diverticulitis risk. JAK inhibitors (tofacitinib, baricitinib) are oral targeted synthetic DMARDs — FDA black box warning for increased risk of serious infections, malignancy, thromboembolism, and cardiovascular events vs. TNF inhibitors. T-cell costimulation inhibitor (abatacept) — preferred with ILD. B-cell depletion (rituximab) — reserved for RF/anti-CCP positive patients failing TNF inhibitors. Combination DMARD therapy (methotrexate + leflunomide or methotrexate + sulfasalazine + hydroxychloroquine 'triple therapy') is an alternative to biologics. Monitoring includes regular...
